Literature DB >> 16030292

A promising new technology for Parkinson's disease.

Ronald F Pfeiffer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16030292     DOI： 10.1212/wnl.65.2_suppl_1.s6

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  12 in total

1.  Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.

Authors:  Willi Cawello; Sascha Ahrweiler; Wladyslaw Sulowicz; Agnieszka Szymczakiewicz-Multanowska; Marina Braun
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 2.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.

Authors:  Weibo Sun; Qingyong Wang; Chuwen Feng; Tiansong Yang; Yuanyuan Qu; Yan Yang; Chaoran Li; Zhongren Sun; Tetsuya Asakawa
Journal:  Neurol Sci       Date:  2022-06-13       Impact factor: 3.830

Review 4.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

5.  Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.

Authors:  Marina Braun; Willi Cawello; Hilmar Boekens; Rolf Horstmann
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

6.  Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial.

Authors:  Willi Cawello; Hans Michael Wolff; Wim J A Meuling; Rolf Horstmann; Marina Braun
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.

Authors:  Willi Cawello; Seong R Kim; Marina Braun; Jan-Peer Elshoff; Junji Ikeda; Tomoo Funaki
Journal:  Clin Drug Investig       Date:  2014-02       Impact factor: 2.859

8.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

9.  Rotigotine transdermal system: a short review.

Authors:  Sabine Bunten; Svenja Happe
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

Review 10.  Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?

Authors:  K Ray Chaudhuri; Alexandra Rizos; Kapil D Sethi
Journal:  J Neural Transm (Vienna)       Date:  2013-03-02       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.